CVS Health Corp. (CVS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151702,
    "name": "CVS Health Corp.",
    "stock_name": "CVS Health Corp.",
    "full_name": "CVS Health Corp.",
    "name_url": "stocks-analysis/cvs-health-corp",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "76.75",
    "chg": 1.75,
    "chgp": "2.33%",
    "dir": 1,
    "prev_price": "75.00",
    "mcapval": "118,762.34",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 3510,
    "indexname": "S&P 500",
    "isin": "US1266501006",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "17.75 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cvs-health-corp-1151702-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "CVS Health Corp. Hits Day Low of $75.92 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cvs-health-corp-hits-day-low-of-7592-amid-price-pressure-3662104",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CVSHealthCorp_priceRelatedfactors_3662104.png",
        "date": "2025-10-31 16:57:06",
        "description": "CVS Health Corp. saw a significant stock decline today, contrasting with the stable S&P 500. Despite a recent downturn, CVS has outperformed the index annually and maintains a strong market position with a high institutional ownership rate and consistent long-term sales growth."
      },
      {
        "title": "CVS Health Faces Weak Start with Significant Gap Down Amid Market Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cvs-health-faces-weak-start-with-significant-gap-down-amid-market-concerns-3712418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CVSHealthCorp_gapdown_3712418.png",
        "date": "2025-10-31 16:39:58",
        "description": "CVS Health Corp. opened with a significant stock price decline, contrasting with the S&P 500's stability. The company has a market capitalization of approximately USD 118.76 billion, a P/E ratio of 17.00, and a notable dividend yield. Financial metrics indicate mixed technical indicators as CVS adapts to market conditions."
      },
      {
        "title": "CVS Health Corp. Hits New 52-Week High of $85.15",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cvs-health-corp-hits-new-52-week-high-of-8515-3659077",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CVSHealthCorp_priceRelatedfactors_3659077.png",
        "date": "2025-10-30 18:20:47",
        "description": "CVS Health Corp. achieved a new 52-week high of USD 85.15 on October 29, 2025, reflecting strong performance in the retail sector. The company has a market capitalization of USD 118.76 billion, a P/E ratio of 17.00, and a notable dividend yield, indicating solid financial health."
      },
      {
        "title": "Is CVS Health Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cvs-health-corp-overvalued-or-undervalued-3637468",
        "imagepath": "",
        "date": "2025-10-21 12:02:53",
        "description": "As of 17 October 2025, CVS Health Corp. has moved from very expensive to expensive, indicating a slight improvement in its valuation stance but still suggesting it is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 17, which is below its peer average of approximately 19.83, and an EV to EBITDA ratio of 9.97, which also indicates a premium compared to its peers. Additionally, the Price to Book Value stands at 1.39, further supporting the notion of overvaluation.\n\nIn comparison to its peers, CVS Health Corp. exhibits a lower P/E ratio than the industry average, while its EV to EBITDA is slightly more favorable than some competitors, suggesting it may not be as attractive as it appears. Notably, the company's recent stock performance has outpaced the S&P 500, with a year-to-date return of 83.83% compared to the S&P 500's 13.30%, but this strong performance is overshadowed ..."
      },
      {
        "title": "CVS Health Corp. Experiences Revision in Score Amidst Market Performance Evaluation",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cvs-health-corp-valuation-grade-downgraded-from-very-expensive-to-expensive-3640558",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CVSHealthCorp_valuationdot_3640558.png",
        "date": "2025-10-20 15:41:55",
        "description": "CVS Health Corp. has adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 1.39. The company has a strong dividend yield and competitive returns compared to the S&P 500, although its long-term performance has been less favorable relative to the index."
      },
      {
        "title": "Is CVS Health Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cvs-health-corp-overvalued-or-undervalued-3634334",
        "imagepath": "",
        "date": "2025-10-20 12:20:36",
        "description": "As of 17 October 2025, the valuation grade for CVS Health Corp. moved from very expensive to expensive, indicating a shift towards a less favorable valuation perspective. The company appears to be overvalued based on its current metrics, including a P/E ratio of 17, which is below the peer average of 19.83, and an EV to EBITDA ratio of 9.97, also lower than the peer comparison. Additionally, the Price to Book Value stands at 1.39, suggesting a premium over its book value.\n\nIn comparison to its peers, CVS Health Corp. is less favorably positioned, with its EV to Sales ratio of 0.43 indicating lower revenue generation relative to enterprise value. Notably, while CVS has shown strong short-term returns, outperforming the S&P 500 with a year-to-date return of 83.83% against 13.30%, its long-term performance over three and five years has lagged significantly behind the index. This mixed performance reinforces th..."
      },
      {
        "title": "Is CVS Health Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cvs-health-corp-overvalued-or-undervalued-3631878",
        "imagepath": "",
        "date": "2025-10-19 11:58:13",
        "description": "As of 17 October 2025, the valuation grade for CVS Health Corp. moved from very expensive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued based on its valuation metrics. The P/E ratio stands at 17, while its peer, which is also in the retailing industry, has a higher P/E of 19.83. Additionally, CVS's EV to EBITDA ratio is 9.97, which is relatively low compared to the peer average, suggesting that the company may not be as attractive as its competitors.\n\nIn terms of returns, CVS Health Corp. has outperformed the S&P 500 over the past year with a return of 29.61% compared to the S&P 500's 14.08%. However, over the longer term, particularly in the 3-year and 10-year periods, CVS has significantly lagged behind the S&P 500, with returns of -9.21% and 38.48%, respectively. This mixed performance reinforces the notion that while the stock m..."
      },
      {
        "title": "CVS Health Corp. Hits New 52-Week High of $81.93",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cvs-health-corp-hits-new-52-week-high-of-8193-3626590",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CVSHealthCorp_priceRelatedfactors_3626590.png",
        "date": "2025-10-16 18:12:00",
        "description": "CVS Health Corp. achieved a new 52-week high of USD 81.93 on October 15, 2025, reflecting strong performance in the retail sector. The company has seen a 33.83% growth over the past year, significantly outperforming the S&P 500, and maintains a solid financial position with a balanced debt-to-equity ratio."
      },
      {
        "title": "CVS Health Corp. Hits New 52-Week High at $79.94",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cvs-health-corp-hits-new-52-week-high-at-7994-3622755",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CVSHealthCorp_priceRelatedfactors_3622755.png",
        "date": "2025-10-15 16:49:28",
        "description": "CVS Health Corp. achieved a new 52-week high of USD 79.94 on October 14, 2025, reflecting strong performance in the retail sector. With a market cap of USD 118.76 billion, a P/E ratio of 17.00, and a dividend yield of 145.25%, the company demonstrates solid financial health and competitive valuation."
      }
    ],
    "total": 22,
    "sid": "1151702",
    "stock_news_url": "https://www.marketsmojo.com/news/cvs-health-corp-1151702"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

CVS Health Corp. Hits Day Low of $75.92 Amid Price Pressure

2025-10-31 16:57:06

CVS Health Corp. saw a significant stock decline today, contrasting with the stable S&P 500. Despite a recent downturn, CVS has outperformed the index annually and maintains a strong market position with a high institutional ownership rate and consistent long-term sales growth.

CVS Health Faces Weak Start with Significant Gap Down Amid Market Concerns

2025-10-31 16:39:58

CVS Health Corp. opened with a significant stock price decline, contrasting with the S&P 500's stability. The company has a market capitalization of approximately USD 118.76 billion, a P/E ratio of 17.00, and a notable dividend yield. Financial metrics indicate mixed technical indicators as CVS adapts to market conditions.

CVS Health Corp. Hits New 52-Week High of $85.15

2025-10-30 18:20:47

CVS Health Corp. achieved a new 52-week high of USD 85.15 on October 29, 2025, reflecting strong performance in the retail sector. The company has a market capitalization of USD 118.76 billion, a P/E ratio of 17.00, and a notable dividend yield, indicating solid financial health.

Is CVS Health Corp. overvalued or undervalued?

2025-10-21 12:02:53

As of 17 October 2025, CVS Health Corp. has moved from very expensive to expensive, indicating a slight improvement in its valuation stance but still suggesting it is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 17, which is below its peer average of approximately 19.83, and an EV to EBITDA ratio of 9.97, which also indicates a premium compared to its peers. Additionally, the Price to Book Value stands at 1.39, further supporting the notion of overvaluation. In comparison to its peers, CVS Health Corp. exhibits a lower P/E ratio than the industry average, while its EV to EBITDA is slightly more favorable than some competitors, suggesting it may not be as attractive as it appears. Notably, the company's recent stock performance has outpaced the S&P 500, with a year-to-date return of 83.83% compared to the S&P 500's 13.30%, but this strong performance is overshadowed ...

CVS Health Corp. Experiences Revision in Score Amidst Market Performance Evaluation

2025-10-20 15:41:55

CVS Health Corp. has adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 1.39. The company has a strong dividend yield and competitive returns compared to the S&P 500, although its long-term performance has been less favorable relative to the index.

Is CVS Health Corp. overvalued or undervalued?

2025-10-20 12:20:36

As of 17 October 2025, the valuation grade for CVS Health Corp. moved from very expensive to expensive, indicating a shift towards a less favorable valuation perspective. The company appears to be overvalued based on its current metrics, including a P/E ratio of 17, which is below the peer average of 19.83, and an EV to EBITDA ratio of 9.97, also lower than the peer comparison. Additionally, the Price to Book Value stands at 1.39, suggesting a premium over its book value. In comparison to its peers, CVS Health Corp. is less favorably positioned, with its EV to Sales ratio of 0.43 indicating lower revenue generation relative to enterprise value. Notably, while CVS has shown strong short-term returns, outperforming the S&P 500 with a year-to-date return of 83.83% against 13.30%, its long-term performance over three and five years has lagged significantly behind the index. This mixed performance reinforces th...

Is CVS Health Corp. overvalued or undervalued?

2025-10-19 11:58:13

As of 17 October 2025, the valuation grade for CVS Health Corp. moved from very expensive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued based on its valuation metrics. The P/E ratio stands at 17, while its peer, which is also in the retailing industry, has a higher P/E of 19.83. Additionally, CVS's EV to EBITDA ratio is 9.97, which is relatively low compared to the peer average, suggesting that the company may not be as attractive as its competitors. In terms of returns, CVS Health Corp. has outperformed the S&P 500 over the past year with a return of 29.61% compared to the S&P 500's 14.08%. However, over the longer term, particularly in the 3-year and 10-year periods, CVS has significantly lagged behind the S&P 500, with returns of -9.21% and 38.48%, respectively. This mixed performance reinforces the notion that while the stock m...

CVS Health Corp. Hits New 52-Week High of $81.93

2025-10-16 18:12:00

CVS Health Corp. achieved a new 52-week high of USD 81.93 on October 15, 2025, reflecting strong performance in the retail sector. The company has seen a 33.83% growth over the past year, significantly outperforming the S&P 500, and maintains a solid financial position with a balanced debt-to-equity ratio.

CVS Health Corp. Hits New 52-Week High at $79.94

2025-10-15 16:49:28

CVS Health Corp. achieved a new 52-week high of USD 79.94 on October 14, 2025, reflecting strong performance in the retail sector. With a market cap of USD 118.76 billion, a P/E ratio of 17.00, and a dividend yield of 145.25%, the company demonstrates solid financial health and competitive valuation.

View All News